Eur J Cancer. 1997 Dec;33(14):2390-2.

A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ.

Source

Department of Oncology, Norwegian Radium Hospital, Oslo, Norway.

Abstract

We searched for a founder mutation in a population from one geographic region of Norway with prevalent breast/ovarian cancer families. We sampled 33 breast/ovarian cancer families and determined haplotypes of four markers linked to the BRCA1 region. Of the affected 33 index women, 13 (39.4%) shared one haplotype. In five (15% of total), an identical mutation was indicated by an abnormal truncated protein test (PTT) of exon 11 and shown to represent a 1675delA mutation. In the other index women, PTT of exon 11 showed no abnormality. No other BRCA1 founder mutation of this prevalence is likely because no other haplotype was more frequent in affecteds than in controls. All families with the 1675delA mutation in this geographic region may be considered as part of one large kindred. This allows a genotype-phenotype correlation to be precisely determined and used in genetic counselling for predictive testing within this kindred. Identification of identical haplotypes between unrelated affected individuals may be used to estimate the extent of founder effects for any mapped disease, without knowledge of the specific founder mutation.

PMID:: 9616287; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Related citations in PubMed

BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations. [Dis Markers. 1999]
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P. Dis Markers. 1999 Oct; 15(1-3):79-84.
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. [Eur J Cancer. 2001]
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, et al. Eur J Cancer. 2001 Nov; 37(16):2082-90.
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. [Fam Cancer. 2004]
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
Muller D, Bonaiti-Pellié C, Abecassis J, Stoppa-Lyonnet D, Fricker JP. Fam Cancer. 2004; 3(1):15-20.
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. [Eur J Hum Genet. 2000]
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrjäkoski K, Kainu T, Vahteristo P, et al. Eur J Hum Genet. 2000 Oct; 8(10):757-63.
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. [Hum Mutat. 2002]
A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aubé J, Hanna D, Narod SA. Hum Mutat. 2002 Nov; 20(5):352-7.

See reviews... See all...

Cited by 4 PubMed Central articles

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. [BMC Cancer. 2005]
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A. BMC Cancer. 2005 Oct 17; 5:134. Epub 2005 Oct 17.
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. [Br J Cancer. 2004]
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A. Br J Cancer. 2004 Nov 15; 91(10):1829-34.
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. [Am J Hum Genet. 2000]
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzańska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, et al. Am J Hum Genet. 2000 Jun; 66(6):1963-8. Epub 2000 Apr 28.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Gene (OMIM)
Gene records associated with Online Mendelian Inheritance in Man (OMIM) records that cite the current articles in their reference lists.
Nucleotide (Weighted)
Nucleotide records associated with the current articles through the Gene database. These are the related sequences on the Gene record that are added manually by NCBI.
OMIM (calculated)
Online Mendelian Inheritance in Man (OMIM) records that include the current articles as references in the light bulb links within or in the citations at the end of the OMIM record. The references available through the light bulb link are collected using the PubMed related articles algorithm to identify records with similar terminology to the OMIM record.
OMIM (cited)
Online Mendelian Inheritance in Man (OMIM) records that include the current articles as reference cited at the end of the OMIM record.
Protein (Weighted)
Protein records associated with the current articles through related Gene database records. These are the related sequences on the Gene record that are added manually by NCBI.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/...
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.
Eur J Cancer. 1997 Dec ;33(14):2390-2.

PubMed
The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors an...
The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1.
Blood. 1998 Jun 15 ;91(12):4523-30.

PubMed
Expression and enzymatic characterization of human glucose phosphate isomerase (...
Expression and enzymatic characterization of human glucose phosphate isomerase (GPI) variants accounting for GPI deficiency.
Blood Cells Mol Dis. 1998 Mar ;24(1):54-61.

PubMed
Antioxidant defences are reduced during the oral glucose tolerance test in norma...
Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects.
Eur J Clin Invest. 1998 Apr ;28(4):329-33.

PubMed
Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline ...
Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
Anticancer Res. 1998 Mar-Apr ;18(2A):739-42.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: